Information de reference pour ce titreAccession Number: | 00004836-200702000-00004.
|
Author: | Fass, Ronnie MD, FACP, FACG
|
Institution: | The Neuro-Enteric Clinical Research Group, Section of Gastroenterology, Southern Arizona VA Health Care System and University of Arizona Health Sciences Center, Tucson, AZ
|
Title: | |
Source: | Journal of Clinical Gastroenterology. 41(2):131-137, February 2007.
|
Abstract: | Nonerosive reflux disease (NERD) and erosive esophagitis are the main presentations of gastroesophageal reflux disease. However, NERD is the most common presentation of gastroesophageal reflux disease in community-based patients. Patients with NERD differ in demographic characteristics from patients with erosive esophagitis, primarily in sex distribution, weight/body mass index, and prevalence of hiatal hernia. Physiologically, patients with NERD tend to have normal lower esophageal sphincter resting pressure, minimal esophageal body motility abnormalities, low esophageal acid exposure profile and minimal nighttime esophageal acid exposure. Patients with NERD have a lower symptom response rate to proton pump inhibitor once daily than patients with erosive esophagitis. Additionally, NERD patients demonstrate a longer lag-time for symptom resolution and lack of difference in symptom response rate between half to full dose proton pump inhibitor as compared with patients with erosive esophagitis.
(C) 2007 Lippincott Williams & Wilkins, Inc.
|
Author Keywords: | heartburn; esophagus; GERD.
|
References: | 1. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314.
2. Locke G III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
3. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management. The Genval workshop report. Gut. 1999;44:S1-S16.
4. Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22:221-227.
5. Nakamura T, Shirakawa K, Masuyama H, et al. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther. 2005;21:19-26.
6. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180.
7. A Gallup Organization National Survey: Heartburn Across America. Princeton: The Gallup Organization Inc; 1988.
8. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953-956.
9. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-124.
10. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1986;21:837-847.
11. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-979.
12. Jones RH, Hungin AP, Phillips J, et al. Gastro-esophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract. 1995;1:149-154.
13. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11:765-773.
14. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119-124.
15. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998;158:2373-2376.
16. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275-285.
17. Chang CS, Poon SK, Lien HC, et al. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol. 1997;92:668-671.
18. Loof L, Gotell P, Elfberg B. The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol. 1993;28:113-118.
19. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907-914.
20. Smout AJPM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther. 1997;11:81-85.
21. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk of gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199-211.
22. Aro P, Ronkainen J, Talley NJ, et al. Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study. Gut. 2005;54:1377-1383.
23. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily; omeprazole 20 mg milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32:965-973.
24. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut. 1994;35:8-14.
25. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37-41.
26. Sontag S, Schnell T, Chejfec G, et al. The benign natural history of GERD: 20 years with rare serious progression [Abstract]. Am J Gastroenterol 1999;94:2601, [sharp]109.
27. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996;38:481-486.
28. McDougall NI, Johnston BT, Collins JS, et al. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol. 1997;9:1161-1167.
29. Manabe N, Yoshihara M, Sasaki A, et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol. 2002;17:949-954.
30. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996;44:532-535.
31. Pace F, Porro GB. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol. 2004;99:946-949.
32. Cameron AJ, Arora AS. Barrett's esophagus and reflux esophagitis: is there a missing link? Am J Gastroenterol. 2002;97:273-278.
33. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103:1241-1245.
34. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451-459.
35. Fitzgerald RC, Farthing MJ. The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum. Curr Gastroenterol Rep. 2000;2:421-424.
36. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
37. Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc. 2002;16:671-673.
38. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98:S2-S7.
39. Quigley EM. Gastro-oesophageal reflux disease-spectrum or continuum? QJM. 1997;90:75-78.
40. Ho KY, Kang JY. Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western Hemisphere. Am J Gastroenterol. 1999;94:1186-1191.
41. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999;94:2054-2059.
42. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology. 2000;119:1439-1446.
43. Martinez SD, Malagon I, Garewal HS, et al. Non-erosive reflux disease (NERD)-is it really just a mild form of gastroesophageal reflux disease (GERD)? [Abstract]. Gastroenterology. 2001;120:A-424, no. 2163.
44. Adachi K, Hashimoto T, Hamamoto N, et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole and rabeprazole. J Gastroenterol Hepatol. 2003;18:1392-1398.
45. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996;111:1192-1199.
46. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol. 2000;95:3071-3080.
47. Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther. 1995;9:145-151.
48. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996;91:1749-1757.
49. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001;15:227-231.
50. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656-665.
51. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996;10:547-555.
52. Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332-1339.
53. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664.
54. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803-1809.
55. Chiba N, De Gara DJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
56. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2004;18:CD002095.
57. Fenton P, Terry ML, Galloway KD, et al. Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? [Abstract]. Gastroenterology. 2000;118:A-481, no. 2600.
58. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. In: Drossman D, ed. Rome II: The Functional Gastrointestinal Disorders. 2nd ed. Lawrence, KS: Allen Press Inc; 2000:275.
59. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
60. Watson RG, Tham TC, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the "sensitive oesophagus". Gut. 1997;40:587-590.
|
Language: | English.
|
Document Type: | Alimentary Tract: Clinical Reviews.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0192-0790
|
NLM Journal Code: | ibg, 7910017
|
DOI Number: | https://dx.doi.org/10.1097/01.mc...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|